Kidney Function After the First Kidney Stone Event

William E Haley, Felicity T Enders, Lisa E. Vaughan, Ramila A. Mehta, Maxton E. Thoman, Terri J Vrtiska, Amy E. Krambeck, John C Lieske, Andrew D Rule

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To determine whether there is a persistent decline in kidney function after the first kidney stone event. Patient and Methods Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. Results There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). Conclusions Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease.

Original languageEnglish (US)
Pages (from-to)1744-1752
Number of pages9
JournalMayo Clinic Proceedings
Volume91
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Kidney Calculi
Creatinine
Kidney
Cystatin C
Serum
Chronic Renal Insufficiency
Proteinuria
Medical Records
Urine

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kidney Function After the First Kidney Stone Event. / Haley, William E; Enders, Felicity T; Vaughan, Lisa E.; Mehta, Ramila A.; Thoman, Maxton E.; Vrtiska, Terri J; Krambeck, Amy E.; Lieske, John C; Rule, Andrew D.

In: Mayo Clinic Proceedings, Vol. 91, No. 12, 01.12.2016, p. 1744-1752.

Research output: Contribution to journalArticle

Haley, William E ; Enders, Felicity T ; Vaughan, Lisa E. ; Mehta, Ramila A. ; Thoman, Maxton E. ; Vrtiska, Terri J ; Krambeck, Amy E. ; Lieske, John C ; Rule, Andrew D. / Kidney Function After the First Kidney Stone Event. In: Mayo Clinic Proceedings. 2016 ; Vol. 91, No. 12. pp. 1744-1752.
@article{33b155b9a15f444da99ac7218c6c3d86,
title = "Kidney Function After the First Kidney Stone Event",
abstract = "Objective To determine whether there is a persistent decline in kidney function after the first kidney stone event. Patient and Methods Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. Results There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4{\%} vs 2.2{\%}; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). Conclusions Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease.",
author = "Haley, {William E} and Enders, {Felicity T} and Vaughan, {Lisa E.} and Mehta, {Ramila A.} and Thoman, {Maxton E.} and Vrtiska, {Terri J} and Krambeck, {Amy E.} and Lieske, {John C} and Rule, {Andrew D}",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.mayocp.2016.08.014",
language = "English (US)",
volume = "91",
pages = "1744--1752",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "12",

}

TY - JOUR

T1 - Kidney Function After the First Kidney Stone Event

AU - Haley, William E

AU - Enders, Felicity T

AU - Vaughan, Lisa E.

AU - Mehta, Ramila A.

AU - Thoman, Maxton E.

AU - Vrtiska, Terri J

AU - Krambeck, Amy E.

AU - Lieske, John C

AU - Rule, Andrew D

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Objective To determine whether there is a persistent decline in kidney function after the first kidney stone event. Patient and Methods Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. Results There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). Conclusions Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease.

AB - Objective To determine whether there is a persistent decline in kidney function after the first kidney stone event. Patient and Methods Incident symptomatic stone formers and age- and sex-matched controls underwent 2 study visits 90 days apart to assess kidney function, complete a survey, and have their medical records reviewed. Kidney function was compared between stone formers and controls adjusting for clinical, blood, and urine risk factors. Results There were 384 stone formers and 457 controls. At visit 1, a median of 104 days after the stone event, stone formers compared with controls had similar serum creatinine (0.86 vs 0.84 mg/dL; P=.23), higher serum cystatin C (0.83 vs 0.72 mg/L; P<.001), higher urine protein (34.2 vs 19.7 mg/24 h; P<.001) levels, and were more likely to have albuminuria (24 h urine albumin >30 mg: 5.4% vs 2.2%; P=.02). Findings were similar after adjustment for risk factors and at visit 2, a median of 92 days after visit 1. In the 173 stone formers with serum creatinine levels from care before study participation, the mean serum creatinine level was 0.84 mg/dL before the stone event, increased to 0.97 mg/dL (P<.001) at the stone event, but returned to 0.85 mg/dL (P=.38) after the stone event (visit 1). Conclusions Incident symptomatic stone formers have a rise in serum creatinine levels that resolves. However, stone formers have sustained higher cystatin C levels and proteinuria that may affect long-term risk of chronic kidney disease.

UR - http://www.scopus.com/inward/record.url?scp=85002539344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002539344&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2016.08.014

DO - 10.1016/j.mayocp.2016.08.014

M3 - Article

VL - 91

SP - 1744

EP - 1752

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 12

ER -